Drug-induced Acute Pancreatitis – ‘Scope for Secondary Prevention’.

I read with interest the article by Chang et al. [1] in which the authors adopt a systematic approach (including taking into account binary clinical conditions such as the presence of hypertriglyceridemia, alcohol and / or tobacco use, gall-stone, obesity and bilio-pancreatic cancers, estimating dose response effects and performing sensitivity analyses) to tease out the relationship of various anti-diabetic drugs and the risk of Acute pancreatitis (AP). In the end, they provide compelling evidence that sulfonylureas carry a more signifi-cant risk of causing AP compared to metformin which in turn carry a more significant risk that dipeptidyl peptidase-4.